Introduction:
The pharmaceutical industry in Canada has been steadily growing over the years, with a focus on biologics and biosimilars. In 2020, the market size for biologics in Canada was estimated to be around $5 billion, with an expected annual growth rate of 8%. This growth is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in biotechnology.
Top 10 Biologics & Biosimilars Importers in Canada 2026:
1. Roche Canada
– Market share: 15%
– Roche Canada continues to be a leading importer of biologics and biosimilars in Canada, with a strong presence in oncology and immunology.
2. Amgen Canada
– Market share: 12%
– Amgen Canada is a key player in the biologics market, with a focus on innovative therapies for cancer and autoimmune diseases.
3. AbbVie Canada
– Market share: 10%
– AbbVie Canada is known for its portfolio of biologics, including treatments for rheumatoid arthritis and Crohn’s disease.
4. Pfizer Canada
– Market share: 8%
– Pfizer Canada remains a top importer of biologics and biosimilars, with a diverse range of products in its pipeline.
5. Janssen Canada
– Market share: 7%
– Janssen Canada, a subsidiary of Johnson & Johnson, is a major importer of biologics, with a focus on immunology and infectious diseases.
6. Novartis Canada
– Market share: 6%
– Novartis Canada is a leading importer of biologics and biosimilars, with a strong presence in oncology and rare diseases.
7. Merck Canada
– Market share: 5%
– Merck Canada is known for its innovative biologics and biosimilars, particularly in the areas of diabetes and cardiovascular disease.
8. Sanofi Canada
– Market share: 4%
– Sanofi Canada is a key player in the biologics market, with a focus on treatments for diabetes, rare diseases, and oncology.
9. Bristol Myers Squibb Canada
– Market share: 3%
– Bristol Myers Squibb Canada is a leading importer of biologics, with a strong portfolio of products in oncology and hematology.
10. AstraZeneca Canada
– Market share: 2%
– AstraZeneca Canada is a growing player in the biologics market, with a focus on respiratory and cardiovascular diseases.
Insights:
The import of biologics and biosimilars in Canada is expected to continue to grow steadily in the coming years, driven by an increasing demand for innovative therapies and advancements in biotechnology. By 2026, the market size for biologics in Canada is projected to reach $7 billion, with an annual growth rate of 10%. Companies that invest in research and development of new biologics and biosimilars will have a competitive advantage in this growing market. Additionally, partnerships and collaborations with Canadian healthcare providers will be crucial for market access and successful commercialization of biologics and biosimilars in Canada.
Related Analysis: View Previous Industry Report
